Early Relapse Is Associated with High Serum Soluble Interleukin-2 Receptor after the Sixth Cycle of R-CHOP Chemotherapy in Patients with Advanced Diffuse Large B-Cell Lymphoma
The clinical significance of serum soluble interleukin-2 receptor (sIL2R) levels was retrospectively assessed in patients with advanced diffuse large B-cell lymphoma (DLBCL). Twenty-one patients, who were newly-diagnosed with advanced DLBCL (stage III and IV) between 2006 and 2009, were evaluated. T...
Gespeichert in:
| Veröffentlicht in: | Anticancer research 2012-11, Vol.32 (11), p.5051-5057 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 5057 |
|---|---|
| container_issue | 11 |
| container_start_page | 5051 |
| container_title | Anticancer research |
| container_volume | 32 |
| creator | YAMAUCHI, Takahiro MATSUDA, Yasufumi YOSHIDA, Akira URASAKI, Yoshimasa IWASAKI, Hiromichi UEDA, Takanori TAKAI, Mihoko TASAKI, Toshiki TAI, Katsunori HOSONO, Naoko NEGORO, Eiju IKEGAYA, Satoshi TAKAGI, Kazutaka KISHI, Shinji |
| description | The clinical significance of serum soluble interleukin-2 receptor (sIL2R) levels was retrospectively assessed in patients with advanced diffuse large B-cell lymphoma (DLBCL). Twenty-one patients, who were newly-diagnosed with advanced DLBCL (stage III and IV) between 2006 and 2009, were evaluated. The median follow-up period was 37 months. All patients received 6-8 cycles of chemotherapy with rituximab in combination with doxorubicin, cyclophosphamide, vincristine, and prednisolone (CHOP)-like regimens and attained complete remission. Although all patients reached complete remission, six patients experienced disease relapse within 1 year after treatment completion. The overall survival was significantly poorer in patients with relapse than in patients with durable remission. The sIL2R levels after the sixth cycle of treatment were significantly higher in the relapse group than in the non-relapse group. Thus, the present study suggests sIL2R levels to be a valuable predictor for the prognosis of patients with advanced DLBCL. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1257782195</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1257782195</sourcerecordid><originalsourceid>FETCH-LOGICAL-p274t-1a20f558b788a6771a564e18560554d2396f13a3a3645e71cab0a11e2c2bd3e13</originalsourceid><addsrcrecordid>eNqFkdtO3EAMhqOKqizQV6jmBombSHPYOezlklIWaSUQW65XTuKQaSeHzkwKeSpekUEs6mXlC0v25_-37E_ZgukVy7UU9ChbUC5primVx9lJCL8oVWplxJfsmAsmJddmkb1cgXczuUcHY0ByE8g6hKGyELEmTza2ZGMfW7JDP3VkN7ipdInqI3qH02_b5zzNVjjGwRNoUpnEFsnOPqfJYq4SPDTkPi82t3ekaLEbUtvDOBPbkzuIFvsY3n3W9V_oq-T63TbNlHbZgn9EcpkX6BzZzt3YDh2cZZ8bcAG_HvJp9vDj6mexybe31zfFepuPXC9jzoDTRkpTamNAac1AqiUyIxWVcllzsVINE5BCLSVqVkFJgTHkFS9rgUycZhfvuqMf_kwY4r6zoUqbQI_DFPaMS60NZyv5f5RpZpKveFP9dkCnssN6P3rbgZ_3H_9IwPkBgFCBa3w6iQ3_OJV0lKHiFXmBlCY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1171860531</pqid></control><display><type>article</type><title>Early Relapse Is Associated with High Serum Soluble Interleukin-2 Receptor after the Sixth Cycle of R-CHOP Chemotherapy in Patients with Advanced Diffuse Large B-Cell Lymphoma</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>YAMAUCHI, Takahiro ; MATSUDA, Yasufumi ; YOSHIDA, Akira ; URASAKI, Yoshimasa ; IWASAKI, Hiromichi ; UEDA, Takanori ; TAKAI, Mihoko ; TASAKI, Toshiki ; TAI, Katsunori ; HOSONO, Naoko ; NEGORO, Eiju ; IKEGAYA, Satoshi ; TAKAGI, Kazutaka ; KISHI, Shinji</creator><creatorcontrib>YAMAUCHI, Takahiro ; MATSUDA, Yasufumi ; YOSHIDA, Akira ; URASAKI, Yoshimasa ; IWASAKI, Hiromichi ; UEDA, Takanori ; TAKAI, Mihoko ; TASAKI, Toshiki ; TAI, Katsunori ; HOSONO, Naoko ; NEGORO, Eiju ; IKEGAYA, Satoshi ; TAKAGI, Kazutaka ; KISHI, Shinji</creatorcontrib><description>The clinical significance of serum soluble interleukin-2 receptor (sIL2R) levels was retrospectively assessed in patients with advanced diffuse large B-cell lymphoma (DLBCL). Twenty-one patients, who were newly-diagnosed with advanced DLBCL (stage III and IV) between 2006 and 2009, were evaluated. The median follow-up period was 37 months. All patients received 6-8 cycles of chemotherapy with rituximab in combination with doxorubicin, cyclophosphamide, vincristine, and prednisolone (CHOP)-like regimens and attained complete remission. Although all patients reached complete remission, six patients experienced disease relapse within 1 year after treatment completion. The overall survival was significantly poorer in patients with relapse than in patients with durable remission. The sIL2R levels after the sixth cycle of treatment were significantly higher in the relapse group than in the non-relapse group. Thus, the present study suggests sIL2R levels to be a valuable predictor for the prognosis of patients with advanced DLBCL.</description><identifier>ISSN: 0250-7005</identifier><identifier>EISSN: 1791-7530</identifier><identifier>PMID: 23155278</identifier><language>eng</language><publisher>Attiki: International Institute of Anticancer Research</publisher><subject>Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Murine-Derived ; Antineoplastic Combined Chemotherapy Protocols ; B-cell lymphoma ; Biological and medical sciences ; Biomarkers, Tumor - analysis ; Biomarkers, Tumor - blood ; Chemotherapy ; Cyclophosphamide ; Doxorubicin ; Enzyme-Linked Immunosorbent Assay ; Female ; Hematologic and hematopoietic diseases ; Humans ; Interleukin 2 ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Lymphoma, Large B-Cell, Diffuse - blood ; Lymphoma, Large B-Cell, Diffuse - drug therapy ; Lymphoma, Large B-Cell, Diffuse - pathology ; Male ; Medical sciences ; Middle Aged ; Neoplasm Recurrence, Local - blood ; Neoplasm Recurrence, Local - drug therapy ; Neoplasm Recurrence, Local - pathology ; Neoplasm Staging ; Prednisolone ; Prednisone ; Prognosis ; Receptors, Interleukin-2 - analysis ; Receptors, Interleukin-2 - blood ; Remission ; Retrospective Studies ; rituximab ; Survival ; Tumors ; Vincristine</subject><ispartof>Anticancer research, 2012-11, Vol.32 (11), p.5051-5057</ispartof><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26605680$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23155278$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>YAMAUCHI, Takahiro</creatorcontrib><creatorcontrib>MATSUDA, Yasufumi</creatorcontrib><creatorcontrib>YOSHIDA, Akira</creatorcontrib><creatorcontrib>URASAKI, Yoshimasa</creatorcontrib><creatorcontrib>IWASAKI, Hiromichi</creatorcontrib><creatorcontrib>UEDA, Takanori</creatorcontrib><creatorcontrib>TAKAI, Mihoko</creatorcontrib><creatorcontrib>TASAKI, Toshiki</creatorcontrib><creatorcontrib>TAI, Katsunori</creatorcontrib><creatorcontrib>HOSONO, Naoko</creatorcontrib><creatorcontrib>NEGORO, Eiju</creatorcontrib><creatorcontrib>IKEGAYA, Satoshi</creatorcontrib><creatorcontrib>TAKAGI, Kazutaka</creatorcontrib><creatorcontrib>KISHI, Shinji</creatorcontrib><title>Early Relapse Is Associated with High Serum Soluble Interleukin-2 Receptor after the Sixth Cycle of R-CHOP Chemotherapy in Patients with Advanced Diffuse Large B-Cell Lymphoma</title><title>Anticancer research</title><addtitle>Anticancer Res</addtitle><description>The clinical significance of serum soluble interleukin-2 receptor (sIL2R) levels was retrospectively assessed in patients with advanced diffuse large B-cell lymphoma (DLBCL). Twenty-one patients, who were newly-diagnosed with advanced DLBCL (stage III and IV) between 2006 and 2009, were evaluated. The median follow-up period was 37 months. All patients received 6-8 cycles of chemotherapy with rituximab in combination with doxorubicin, cyclophosphamide, vincristine, and prednisolone (CHOP)-like regimens and attained complete remission. Although all patients reached complete remission, six patients experienced disease relapse within 1 year after treatment completion. The overall survival was significantly poorer in patients with relapse than in patients with durable remission. The sIL2R levels after the sixth cycle of treatment were significantly higher in the relapse group than in the non-relapse group. Thus, the present study suggests sIL2R levels to be a valuable predictor for the prognosis of patients with advanced DLBCL.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antibodies, Monoclonal, Murine-Derived</subject><subject>Antineoplastic Combined Chemotherapy Protocols</subject><subject>B-cell lymphoma</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - analysis</subject><subject>Biomarkers, Tumor - blood</subject><subject>Chemotherapy</subject><subject>Cyclophosphamide</subject><subject>Doxorubicin</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>Female</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Humans</subject><subject>Interleukin 2</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Lymphoma, Large B-Cell, Diffuse - blood</subject><subject>Lymphoma, Large B-Cell, Diffuse - drug therapy</subject><subject>Lymphoma, Large B-Cell, Diffuse - pathology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local - blood</subject><subject>Neoplasm Recurrence, Local - drug therapy</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>Neoplasm Staging</subject><subject>Prednisolone</subject><subject>Prednisone</subject><subject>Prognosis</subject><subject>Receptors, Interleukin-2 - analysis</subject><subject>Receptors, Interleukin-2 - blood</subject><subject>Remission</subject><subject>Retrospective Studies</subject><subject>rituximab</subject><subject>Survival</subject><subject>Tumors</subject><subject>Vincristine</subject><issn>0250-7005</issn><issn>1791-7530</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkdtO3EAMhqOKqizQV6jmBombSHPYOezlklIWaSUQW65XTuKQaSeHzkwKeSpekUEs6mXlC0v25_-37E_ZgukVy7UU9ChbUC5primVx9lJCL8oVWplxJfsmAsmJddmkb1cgXczuUcHY0ByE8g6hKGyELEmTza2ZGMfW7JDP3VkN7ipdInqI3qH02_b5zzNVjjGwRNoUpnEFsnOPqfJYq4SPDTkPi82t3ekaLEbUtvDOBPbkzuIFvsY3n3W9V_oq-T63TbNlHbZgn9EcpkX6BzZzt3YDh2cZZ8bcAG_HvJp9vDj6mexybe31zfFepuPXC9jzoDTRkpTamNAac1AqiUyIxWVcllzsVINE5BCLSVqVkFJgTHkFS9rgUycZhfvuqMf_kwY4r6zoUqbQI_DFPaMS60NZyv5f5RpZpKveFP9dkCnssN6P3rbgZ_3H_9IwPkBgFCBa3w6iQ3_OJV0lKHiFXmBlCY</recordid><startdate>20121101</startdate><enddate>20121101</enddate><creator>YAMAUCHI, Takahiro</creator><creator>MATSUDA, Yasufumi</creator><creator>YOSHIDA, Akira</creator><creator>URASAKI, Yoshimasa</creator><creator>IWASAKI, Hiromichi</creator><creator>UEDA, Takanori</creator><creator>TAKAI, Mihoko</creator><creator>TASAKI, Toshiki</creator><creator>TAI, Katsunori</creator><creator>HOSONO, Naoko</creator><creator>NEGORO, Eiju</creator><creator>IKEGAYA, Satoshi</creator><creator>TAKAGI, Kazutaka</creator><creator>KISHI, Shinji</creator><general>International Institute of Anticancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>20121101</creationdate><title>Early Relapse Is Associated with High Serum Soluble Interleukin-2 Receptor after the Sixth Cycle of R-CHOP Chemotherapy in Patients with Advanced Diffuse Large B-Cell Lymphoma</title><author>YAMAUCHI, Takahiro ; MATSUDA, Yasufumi ; YOSHIDA, Akira ; URASAKI, Yoshimasa ; IWASAKI, Hiromichi ; UEDA, Takanori ; TAKAI, Mihoko ; TASAKI, Toshiki ; TAI, Katsunori ; HOSONO, Naoko ; NEGORO, Eiju ; IKEGAYA, Satoshi ; TAKAGI, Kazutaka ; KISHI, Shinji</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p274t-1a20f558b788a6771a564e18560554d2396f13a3a3645e71cab0a11e2c2bd3e13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antibodies, Monoclonal, Murine-Derived</topic><topic>Antineoplastic Combined Chemotherapy Protocols</topic><topic>B-cell lymphoma</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - analysis</topic><topic>Biomarkers, Tumor - blood</topic><topic>Chemotherapy</topic><topic>Cyclophosphamide</topic><topic>Doxorubicin</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>Female</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Humans</topic><topic>Interleukin 2</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Lymphoma, Large B-Cell, Diffuse - blood</topic><topic>Lymphoma, Large B-Cell, Diffuse - drug therapy</topic><topic>Lymphoma, Large B-Cell, Diffuse - pathology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local - blood</topic><topic>Neoplasm Recurrence, Local - drug therapy</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>Neoplasm Staging</topic><topic>Prednisolone</topic><topic>Prednisone</topic><topic>Prognosis</topic><topic>Receptors, Interleukin-2 - analysis</topic><topic>Receptors, Interleukin-2 - blood</topic><topic>Remission</topic><topic>Retrospective Studies</topic><topic>rituximab</topic><topic>Survival</topic><topic>Tumors</topic><topic>Vincristine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>YAMAUCHI, Takahiro</creatorcontrib><creatorcontrib>MATSUDA, Yasufumi</creatorcontrib><creatorcontrib>YOSHIDA, Akira</creatorcontrib><creatorcontrib>URASAKI, Yoshimasa</creatorcontrib><creatorcontrib>IWASAKI, Hiromichi</creatorcontrib><creatorcontrib>UEDA, Takanori</creatorcontrib><creatorcontrib>TAKAI, Mihoko</creatorcontrib><creatorcontrib>TASAKI, Toshiki</creatorcontrib><creatorcontrib>TAI, Katsunori</creatorcontrib><creatorcontrib>HOSONO, Naoko</creatorcontrib><creatorcontrib>NEGORO, Eiju</creatorcontrib><creatorcontrib>IKEGAYA, Satoshi</creatorcontrib><creatorcontrib>TAKAGI, Kazutaka</creatorcontrib><creatorcontrib>KISHI, Shinji</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Anticancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>YAMAUCHI, Takahiro</au><au>MATSUDA, Yasufumi</au><au>YOSHIDA, Akira</au><au>URASAKI, Yoshimasa</au><au>IWASAKI, Hiromichi</au><au>UEDA, Takanori</au><au>TAKAI, Mihoko</au><au>TASAKI, Toshiki</au><au>TAI, Katsunori</au><au>HOSONO, Naoko</au><au>NEGORO, Eiju</au><au>IKEGAYA, Satoshi</au><au>TAKAGI, Kazutaka</au><au>KISHI, Shinji</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Early Relapse Is Associated with High Serum Soluble Interleukin-2 Receptor after the Sixth Cycle of R-CHOP Chemotherapy in Patients with Advanced Diffuse Large B-Cell Lymphoma</atitle><jtitle>Anticancer research</jtitle><addtitle>Anticancer Res</addtitle><date>2012-11-01</date><risdate>2012</risdate><volume>32</volume><issue>11</issue><spage>5051</spage><epage>5057</epage><pages>5051-5057</pages><issn>0250-7005</issn><eissn>1791-7530</eissn><abstract>The clinical significance of serum soluble interleukin-2 receptor (sIL2R) levels was retrospectively assessed in patients with advanced diffuse large B-cell lymphoma (DLBCL). Twenty-one patients, who were newly-diagnosed with advanced DLBCL (stage III and IV) between 2006 and 2009, were evaluated. The median follow-up period was 37 months. All patients received 6-8 cycles of chemotherapy with rituximab in combination with doxorubicin, cyclophosphamide, vincristine, and prednisolone (CHOP)-like regimens and attained complete remission. Although all patients reached complete remission, six patients experienced disease relapse within 1 year after treatment completion. The overall survival was significantly poorer in patients with relapse than in patients with durable remission. The sIL2R levels after the sixth cycle of treatment were significantly higher in the relapse group than in the non-relapse group. Thus, the present study suggests sIL2R levels to be a valuable predictor for the prognosis of patients with advanced DLBCL.</abstract><cop>Attiki</cop><pub>International Institute of Anticancer Research</pub><pmid>23155278</pmid><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0250-7005 |
| ispartof | Anticancer research, 2012-11, Vol.32 (11), p.5051-5057 |
| issn | 0250-7005 1791-7530 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1257782195 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Aged Aged, 80 and over Antibodies, Monoclonal, Murine-Derived Antineoplastic Combined Chemotherapy Protocols B-cell lymphoma Biological and medical sciences Biomarkers, Tumor - analysis Biomarkers, Tumor - blood Chemotherapy Cyclophosphamide Doxorubicin Enzyme-Linked Immunosorbent Assay Female Hematologic and hematopoietic diseases Humans Interleukin 2 Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Lymphoma, Large B-Cell, Diffuse - blood Lymphoma, Large B-Cell, Diffuse - drug therapy Lymphoma, Large B-Cell, Diffuse - pathology Male Medical sciences Middle Aged Neoplasm Recurrence, Local - blood Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - pathology Neoplasm Staging Prednisolone Prednisone Prognosis Receptors, Interleukin-2 - analysis Receptors, Interleukin-2 - blood Remission Retrospective Studies rituximab Survival Tumors Vincristine |
| title | Early Relapse Is Associated with High Serum Soluble Interleukin-2 Receptor after the Sixth Cycle of R-CHOP Chemotherapy in Patients with Advanced Diffuse Large B-Cell Lymphoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T01%3A45%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Early%20Relapse%20Is%20Associated%20with%20High%20Serum%20Soluble%20Interleukin-2%20Receptor%20after%20the%20Sixth%20Cycle%20of%20R-CHOP%20Chemotherapy%20in%20Patients%20with%20Advanced%20Diffuse%20Large%20B-Cell%20Lymphoma&rft.jtitle=Anticancer%20research&rft.au=YAMAUCHI,%20Takahiro&rft.date=2012-11-01&rft.volume=32&rft.issue=11&rft.spage=5051&rft.epage=5057&rft.pages=5051-5057&rft.issn=0250-7005&rft.eissn=1791-7530&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E1257782195%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1171860531&rft_id=info:pmid/23155278&rfr_iscdi=true |